Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Relay Therapeutics (RLAY) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Rly-8161Nras G12d, Nras G12v, Nras G13d, Advanced Nras-Mutant Melanoma, Advanced Nras-Mutant Solid Tumors, Nras Mutation, Nras G13r, Nras Q61r, Nras Q61k, Nras Q61l, Nras Q61hPhase IRecruitingA First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid TumorsApr 28, 2026―
Fulvestrant, Capivasertib, Rly-2608Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Positive Tumor, Pik3ca Mutation, Her2- Negative Breast CancerPhase IIIRecruitingPhase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerMay 08, 2025―
Rly-2608Pik3ca Mutation, Pik3ca-Related Overgrowth Spectrum (Pros), Lymphatic Malformations, Vascular Malformations, Cloves Syndrome, Klippel Trenaunay Syndrome, Megalencephaly-Capillary Malformation Polymicrogyria Syndrome (Mcap)Phase IIRecruitingA Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)Jan 17, 2025
Abemaciclib, Ribociclib, Palbociclib, Fulvestrant, Rly-5836Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Positive Tumor, Solid Tumor, Adult, Unresectable Solid Tumor, Her2-Negative Breast Cancer, Pik3ca MutationPhase ICompletedFirst-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid TumorsJan 23, 2023―
Fulvestrant, Rly-2608, Palbociclib 125Mg, Ribociclib 400Mg, Ribociclib 600Mg, Pf-07220060 100Mg, Pf-07220060 300 MgEndometrial Cancer, Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Solid Tumor, Adult, Unresectable Solid Tumor, Her2-Negative Breast Cancer, Pik3ca MutationPhase IRecruitingFirst-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast CancerDec 20, 2021―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Relay Therapeutics Inc (RLAY) have in its pipeline
Relay Therapeutics RLAY is currently developing the following drugs: Rly-8161, Fulvestrant, Capivasertib, Rly-2608, Rly-2608, Abemaciclib, Ribociclib, Palbociclib, Fulvestrant, Rly-5836, Fulvestrant, Rly-2608, Palbociclib 125Mg, Ribociclib 400Mg, Ribociclib 600Mg, Pf-07220060 100Mg, Pf-07220060 300 Mg. These drug candidates are in various stages of clinical development as the company works toward FDA approval.